Actos Time Line: The Fraught History Behind Takeda Pharmaceutical’s Diabetes Drug
It has now come to light that Takeda Pharmaceuticals knew about the cancer risks associated with the ingestion of Actos, a drug they developed to treat type 2 diabetes. However, despite these known Actos bladder cancer risks, Takeda Pharmaceuticals began marketing and selling the drug upon U.S. Food and Drug Administration (FDA) approval in 1999.
The following time line offers a detailed look into the fraught history of Actos, from its approval to the current day legal proceedings:
- July 1999 – The FDA approved Actos for the treatment of type 2 diabetes.
- 2002 – The risk of heart failure while taking Actos became apparent, and as a result, the FDA required the Actos label to be updated with information about heart failure risks.
- 2007 – The FDA mandated that the Actos label be updated to include a black-box warning about the Actos heart failure risks.
- September 17, 2010 – After reviewing data from a 10-year epidemiological study funded by Takeda Pharmaceuticals, the FDA made an announcement that it would begin an its own investigation into the safety of Actos, and in particular the bladder cancer risk.
- June 2011 – France announced discontinued Actos prescriptions and sales as a result of data gathered in an Actos study conducted by the French Medicines Agency from 2006 to 2009, which revealed a strong link between Actos and the development of bladder cancer.
- June 2011 – The FDA released a warning about the risks of bladder cancer and Actos. The FDA warning mentioned that when Actos is taken for more than 12 months, there is an increased risk of developing bladder cancer. The FDA demanded the Actos label be updated with information about the bladder cancer risks.
- July 12, 2011 – Takeda Pharmaceuticals issued an Actos recall in France.
- July 21, 2011 – The European Medicines Agency ruled to keep Actos on the drug market, but made a recommendation that healthcare providers closely monitor patients taking Actos for any signs of bladder cancer. The EMA also recommended that a thorough screening process be established when considering prescribing Actos to new patients.
- August 4, 2011 – The FDA (approved new warning label information about) the risk of developing bladder cancer while taking Actos.
- September 2011 – The first Actos class action lawsuit is filed in Louisiana.
- December 2011 – Actos lawsuits are consolidated into a Multidistrict Litigation (MDL) in Louisiana.
- March 2012 – A former Takeda Pharmaceuticals employee, Dr. Helen Ge, sued Takeda Pharmaceuticals claiming that the pharmaceutical company deliberately withheld information about the safety of Actos from the FDA.
- December 2012 – Defective drug lawyers at Carey Danis & Lowe are currently accepting Actos claims.
If you or a loved one has suffered from Actos bladder cancer, you may be entitled to receive compensation for your suffering and losses. Our experienced defective drug lawyers will provide you with the expert legal counsel required to hold Takeda Pharmaceuticals responsible for marketing and selling the defective drug, Actos.
For a free legal consultation regarding your Actos claim, contact a lawyer at Carey Danis & Lowe at 800.721.2519.
References: Actos, Pharmaceutical litigation
Tags: Actos, bladder cancer, Carey Danis Lowe, defective, FDA, France, French Medicines Agency, Helen Ge, lawsuit, Takeda Pharmaceuticals